Nakano Yukiko, Shimizu Wataru
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
JACC Asia. 2022 Jul 19;2(4):412-421. doi: 10.1016/j.jacasi.2022.03.011. eCollection 2022 Aug.
Brugada syndrome (BrS) is one of the main inherited arrhythmia syndromes causing ventricular fibrillation (VF) and sudden cardiac death in young to middle-aged men, especially in Asians. The diagnosis of BrS is based on spontaneous or drug-provoked type 1 Brugada electrocardiogram. The current reliable therapy for BrS patients with VF history is the implantation of an implantable cardioverter-defibrillator. As for BrS patients without VF history, how asymptomatic BrS patients should effectively be treated is still uncertain because risk stratification of the BrS is still inadequate. Various parameters and combinations of several parameters have been reported for risk stratification of BrS. The gene is believed to be the only gene that is responsible for BrS, and it has been reported to be useful for risk stratification. This review focuses on risk stratification of BrS patients, and focuses specifically on BrS patients of Asian descent.
Brugada综合征(BrS)是导致中青年男性,尤其是亚洲男性发生心室颤动(VF)和心源性猝死的主要遗传性心律失常综合征之一。BrS的诊断基于自发或药物诱发的1型Brugada心电图。对于有VF病史的BrS患者,目前可靠的治疗方法是植入植入式心脏复律除颤器。对于没有VF病史的BrS患者,由于BrS的风险分层仍不完善,无症状的BrS患者应如何有效治疗仍不确定。已经报道了各种参数以及几个参数的组合用于BrS的风险分层。该基因被认为是唯一导致BrS的基因,并且据报道它对风险分层有用。本综述重点关注BrS患者的风险分层,特别是亚洲血统的BrS患者。